Form 8-K - Current report:
SEC Accession No. 0001140361-24-048238
Filing Date
2024-12-03
Accepted
2024-12-03 07:20:26
Documents
14
Period of Report
2024-12-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20039426_8k.htm   iXBRL 8-K 29615
2 EXHIBIT 99.1 ef20039426_ex99-1.htm EX-99.1 18736
  Complete submission text file 0001140361-24-048238.txt   191349

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20241203.xsd EX-101.SCH 3980
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20241203_lab.xml EX-101.LAB 21967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20241203_pre.xml EX-101.PRE 16043
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20039426_8k_htm.xml XML 4208
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 241521063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)